EchoNous Secures FDA Clearance for Hand-Held Ultrasound Scanner
Eight-ounce scanner assesses heart function.
The U.S. Food & Drug Administration (FDA) has awarded 510(k) clearance to the hand-held ultrasound platform Kosmos, produced by the developer EchoNous.
By using machine learning, Kosmos can imitate humans’ learning and decision-making processes, according to the company. The 8-oz ultrasound tool has embedded and synchronized ECG and digital auscultation. Currently, the tool measures systolic heart function.
In addition, EchoNous has side-stepped the need for cloud connectivity with the Kosmos Bridge, a tablet that accompanies the platform. All artificial intelligence functions run on the tablet, ensuring there are no service failures during scans, EchoNous officials said. It is also designed to connect with a health system's IT system without a need for internet connectivity.
According to EchoNous officials, the Kosmos platform has been tested with more than 300 patients in acute care settings in the United States, Canada, Europe, and Japan. It will be available in the U.S. market for less than $10,000.
As a next step, company officials said, EchoNous plans to file for FDA clearance for a trio of algorithms that will allow users use machine learning algorithms to grade image quality, guide their technique, and label heart anatomy.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound
April 4th 2025In a study recently presented at the American College of Cardiology (ACC) conference, researchers found that novice use of AI-guided cardiac ultrasound after an AI-enabled electrocardiogram increased the positive predictive value for reduced left ventricular ejection fraction (LVEF) or aortic valve stenosis by 33 percent.
